EL CAPITAN Anterior Lumbar Interbody Fusion System
K214047 · Astura Medical · OVD · Mar 30, 2022 · Orthopedic
Device Facts
Record ID
K214047
Device Name
EL CAPITAN Anterior Lumbar Interbody Fusion System
Applicant
Astura Medical
Product Code
OVD · Orthopedic
Decision Date
Mar 30, 2022
Decision
SESE
Submission Type
Traditional
Regulation
21 CFR 888.3080
Device Class
Class 2
Attributes
Therapeutic
Intended Use
The El Capitan Anterior Lumbar Interbody System is indicated for intervertebral body fusion procedures in sketally mature patients with degenerative disc disease (DDD) of the lumbar spine at one or two contiguous levels from L1-L2 to L5-S1. DDD is defined as discogenic pain with degeneration of the disc confirmed by history and radiosraphic studies. These DDD patients may also have up to Grade I spondylolisthesis at the involved level(s). El Capitan System implants are to be used with autogenous bone graft and supplemental fixation. Patients should have at least six (0) months of non-operative weatment prior to treatment with an intervertebral cage. The EL CAPITAN Spacer and Plate assembly are an integrated interbody fusion device intended for stand-alone use when used with all titanium alloy screws. When used with anchors only the zero plate may be used and the assembly is intended for use with additional supplemental fixation that has been cleared by the FDA for use in the lumbar spine. Hyperlordotic interbody devices (>20° lordosis) and the Oblique interbody devices must be used with supplemental fixation (e.g. posterior fixation) that has been cleared by the FDA for use in the lumbar spine.
Device Story
The El Capitan Anterior Lumbar Interbody Fusion System is a modular, two-piece intervertebral body fusion device consisting of interchangeable spacers and plates. It is designed to replace autogenous bone graft blocks, reducing donor site complications. The device features a spring-loaded latch mechanism for intraoperative assembly. Implants are hollow to accommodate autogenous bone graft, promoting arthrodesis through open superior and inferior surfaces. The system is used by surgeons in clinical settings for lumbar spinal fusion. It can function as a stand-alone device when used with titanium alloy screws or with additional FDA-cleared supplemental fixation. Hyperlordotic and oblique variants require mandatory supplemental posterior fixation. The device provides structural support to the intervertebral space, facilitating bone growth and stabilizing the spinal segment to alleviate discogenic pain.
Clinical Evidence
No clinical studies were performed. Equivalence is supported by non-clinical bench testing, including static and dynamic compression, static and dynamic compression shear, subsidence, and expulsion testing per ASTM standards.
Technological Characteristics
Materials: PEEK-OPTIMA LT120HA (MAF 2227), Tantalum (ASTM F560), Titanium Alloy (ASTM F136), Nitinol (ASTM E2063). Modular 2-piece design with spring-loaded latch. Hollow geometry for bone graft. Mechanical testing per ASTM F2077, F1717, F2267.
Indications for Use
Indicated for skeletally mature patients with lumbar degenerative disc disease (DDD) at one or two contiguous levels (L1-L2 to L5-S1) with or without Grade I spondylolisthesis/retrolisthesis. Requires 6 months of failed non-operative treatment.
Regulatory Classification
Identification
An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.
Special Controls
*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
*Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
Predicate Devices
EL CAPITAN Anterior Lumbar Interbody Fusion (K192492)
K181531 — SpineEX Sagittae Lateral Lumbar Interbody Fusion Devices · Spineex, Inc. · Oct 5, 2018
K220953 — ChoiceSpine TigerShark M, Modular Interbody System · Choice Spine, LLC · Sep 13, 2022
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. Underneath the square are the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.
March 30, 2022
Astura Medical Parker Kelch Quality Manager 4949 W Royal Ln. Irving, Texas 75063
Re: K214047
Trade/Device Name: EL CAPITAN Anterior Lumbar Interbody Fusion System Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral Body Fusion Device Regulatory Class: Class II Product Code: OVD Dated: March 17, 2022 Received: March 17, 2022
Dear Parker Kelch:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
{1}------------------------------------------------
statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
for
Brent Showalter, Ph.D. Assistant Director DHT6B: Division of Spinal Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
# Indications for Use
510(k) Number (if known)
K214047
Device Name EL CAPITAN ANTERIOR LUMBAR INTERBODY SYSTEM
#### Indications for Use (Describe)
The El Capitan Anterior Lumbar Interbody System is indicated for intervertebral body fusion procedures in sketally mature patients with degenerative disc disease (DDD) of the lumbar spine at one or two contiguous levels from L1-L2 to L5-S1. DDD is defined as discogenic pain with degeneration of the disc confirmed by history and radiosraphic studies. These DDD patients may also have up to Grade I spondylolisthesis at the involved level(s). El Capitan System implants are to be used with autogenous bone graft and supplemental fixation. Patients should have at least six (0) months of non-operative weatment prior to treatment with an intervertebral cage.
The EL CAPITAN Spacer and Plate assembly are an integrated interbody fusion device intended for stand-alone use when used with all titanium alloy screws. When used with anchors only the zero plate may be used and the assembly is intended for use with additional supplemental fixation that has been cleared by the FDA for use in the lumbar spine.
Hyperlordotic interbody devices (>20° lordosis) and the Oblique interbody devices must be used with supplemental fixation (e.g. posterior fixation) that has been cleared by the FDA for use in the lumbar spine.
| Type of Use (Select one or both, as applicable) | | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|
| <table style="border:none"><tr><td><div> <span> <span style="font-size:16px">☒</span> Prescription Use (Part 21 CFR 801 Subpart D) </span> </div></td><td><div> <span> <span style="font-size:16px">☐</span> Over-The-Counter Use (21 CFR 801 Subpart C) </span> </div></td></tr></table> | <div> <span> <span style="font-size:16px">☒</span> Prescription Use (Part 21 CFR 801 Subpart D) </span> </div> | <div> <span> <span style="font-size:16px">☐</span> Over-The-Counter Use (21 CFR 801 Subpart C) </span> </div> |
| <div> <span> <span style="font-size:16px">☒</span> Prescription Use (Part 21 CFR 801 Subpart D) </span> </div> | <div> <span> <span style="font-size:16px">☐</span> Over-The-Counter Use (21 CFR 801 Subpart C) </span> </div> | |
## CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW! *
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
## 510(k) Summary: EL CAPITAN Anterior Lumbar Interbody Fusion
| Date Prepared | March 16, 2022 |
|------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Submitted By | Astura Medical |
| | 4949 W Royal Ln |
| | Irving, TX 75063 |
| Contact | Parker Kelch |
| | 4949 W Royal Ln |
| | Irving, TX 75063 |
| | Phone: 469-501-5530 x503 |
| | Email: quality@asturamedical.com |
| Trade Name | EL CAPITAN Anterior Lumbar Interbody Fusion System |
| Common Name | Intervertebral body fusion device |
| Classification Name | Intervertebral body fusion device - lumbar |
| Class | II |
| Product Code | OVD |
| CFR Section | 21 CFR section 888.3080 |
| Device Panel | Orthopedic |
| Primary Predicate Device | EL CAPITAN Anterior Lumbar Interbody Fusion (K192492) |
| Additional Predicate | Half Dome (K152512, K182877) |
| Device(s) | Spinal Elements Lucent Magnum (K083475) |
| Device Description | The El Capitan Anterior Lumbar Interbody devices are implants developed |
| | for the substitution of the classical autogenous bone graft blocks. The |
| | cages assist to avoid complications related to the bone graft donation site |
| | (chronic pain, hematoma, infection, bone removal from the donor site |
| | making it impossible to remove bone again, quality of the iliac bone, |
| | accessing a healthy donor site that may become an unhealthy site, |
| | hernias by the incision). The Spacers are a 2-piece modular design which |
| | allows for interchangeable plate and spacer components. The plate and |
| | spacer components contain interlocking features in addition to a spring- |
| | loaded latch mechanism which allows for intraoperative assembly prior to |
| | implantation. The spacer components are available in a range of |
| | footprints and heights, and the plates are offered in multiple fixation |
| | types and sizes to suit the individual pathology and anatomical conditions |
| | of the patient. The implants have a hollow center to allow placement of |
| | autogenous bone graft. The superior and inferior surfaces are open to<br>promote contact of the bone graft with the vertebral end plates, allowing |
| | bone growth (arthrodesis). |
| Materials | PEEK-OPTIMA LT120HA (PEEK-OPTIMA HA Enhanced) – MAF 2227 |
| | Tantalum per ASTM F560 |
| | Titanium Alloy (Ti6-AL4-V ELI) per ASTM F136 |
| | Nitinol #1 (ASTM E2063) |
| | |
| Substantial Equivalence<br>Claimed to Predicate<br>Devices | The El Capitan Anterior Lumbar Interbody System is substantially<br>equivalent to the predicate devices in terms of intended use, design,<br>materials used, mechanical safety and performances. |
| Indications for Use | The El Capitan Anterior Lumbar Interbody System is indicated for<br>intervertebral body fusion procedures in skeletally mature patients with<br>degenerative disc disease (DDD) of the lumbar spine at one or two<br>contiguous levels from L1-L2 to L5-S1. DDD is defined as discogenic pain<br>with degeneration of the disc confirmed by history and radiographic<br>studies. These DDD patients may also have up to Grade I spondylolisthesis<br>or retrolisthesis at the involved level(s). El Capitan System implants are to<br>be used with autogenous bone graft and supplemental fixation. Patients<br>should have at least six (6) months of non-operative treatment prior to<br>treatment with an intervertebral cage.<br><br>The EL CAPITAN Spacer and Plate assembly are an integrated interbody<br>fusion device intended for stand-alone use when used with all titanium<br>alloy screws. When used with anchors only the zero plate may be used<br>and the assembly is intended for use with additional supplemental<br>fixation that has been cleared by the FDA for use in the lumbar spine.<br><br>Hyperlordotic interbody devices (>20° lordosis) and the Oblique interbody<br>devices must be used with supplemental fixation (e.g. posterior fixation)<br>that has been cleared by the FDA for use in the lumbar spine. |
| Non-clinical Test<br>Summary | The following analyses were conducted:<br>Static Compression ASTM F2077 Dynamic Compression ASTM F1717 Static Compression Shear ASTM F2077 Dynamic Compression Shear ASTM F1717 Subsidence ASTM F2267 Expulsion The results of these evaluations indicate that the El Capitan implants are<br>equivalent to predicate devices. |
| Clinical Test Summary | No clinical studies were performed |
| Conclusions: Non-Clinical<br>and Clinical | Astura Medical considers the El Capitan Anterior Lumbar Interbody<br>System to be equivalent to the predicate devices listed above. This<br>conclusion is based upon the devices' similarities in principles of<br>operation, technology, materials and indications for use. |
In accordance with 21 CFR 807.92 of the Federal Code of Regulations
{4}------------------------------------------------
Panel 1
/
Sort by
Ready
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.
Sort by:
Create Alert
Search Filters
Agent Token
Create a read-only bearer token for Claude, ChatGPT, or other agents that can call HTTP APIs.